<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479075</url>
  </required_header>
  <id_info>
    <org_study_id>Centrin</org_study_id>
    <nct_id>NCT01479075</nct_id>
  </id_info>
  <brief_title>The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism</brief_title>
  <acronym>Centrin</acronym>
  <official_title>The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin has a direct effect on the energy metabolism of the brain under basal conditions and
      has an effect on the hepatic glucose production, lipid metabolism and the secretion of
      various hormone. The effect of intranasal insulin on peripheral metabolism in humans
      supposedly is mediated by the vagus nerve.

      The purpose of this study is to determine whether central insulin influences the human
      peripheral insulin sensitivity of liver and muscle and whether vagus nerve stimulation can
      mimick this effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin has a direct effect on the energy metabolism of the brain under basal conditions and
      has an effect on the hepatic glucose production, lipid metabolism in the mouse model.

      The purpose of this study is to determine whether central insulin influences the human
      peripheral insulin sensitivity of liver and muscle and energy metabolism. Intranasal insulin
      can be used in humans to deliver insulin to the brain and studies have shown that intranasal
      insulin might reduce food intake, lower body weight and modulate muscle glucose and adipose
      tissue lipid metabolism in himans. These effects are likely mediated by the vagus nerve as
      skeletal muscle insulin sensitization after intranasal insulin relates to parasympathetic
      tone activity (Heni et al. Diabetes 2014). Transcutaneous auricular vagus nerve stimulation
      (taVNS) activates non-invasively the sensory branches of the vagus nerve and is applied in
      humans as adjuvant treatment in drug-resistant epilepsy (Frangos et al. 2015). Thereby it can
      be used to examine whether the vagus nerve indeed mediates brain insulin signals to the
      periphery.

      Here we aim to investigate the effects of intranasal insulin on hepatic glucose, lipid and
      energy metabolism. We further aim to test whether taVNS can mimick intranasal insulin effects
      on peripheral metabolism in humans.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of insulin sensitivity with gold standard methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Energy metabolism is assessed from gold standard methods</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>intranasal insulin in patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal insulin is applied to diabetic patients under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intransal insulin in study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intranasal insulin is applied to healthy patients under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo in patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo in study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo spray is applied intranasally in healthy participants under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>taNVS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham stimulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham stimulation in the ear lobe is applied for 14 min in healthy participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intransal insulin</intervention_name>
    <description>4x 40mU intranasal insulin</description>
    <arm_group_label>intranasal insulin in patients</arm_group_label>
    <arm_group_label>intransal insulin in study participants</arm_group_label>
    <other_name>intranasal insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo in patients</arm_group_label>
    <arm_group_label>placebo in study participants</arm_group_label>
    <other_name>intranasal placebo spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>taVNS</intervention_name>
    <arm_group_label>taNVS</arm_group_label>
    <other_name>transcutaneous auricular vagus nerve stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham stimulation</intervention_name>
    <arm_group_label>Sham stimulation</arm_group_label>
    <other_name>sham stimulation in the ear lobe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 30 and ≤ 70 years

          -  balanced gender ratio (50: 50)

          -  BMI 20-25 kg/m² (normal weight subjects)

          -  BMI 25-35 kg/m² (obese subjects)

        Exclusion Criteria:

          -  acute illness within the last 2 weeks before the examination

          -  autoimmune diseases and disorders immune- compromised (leukocytes &lt;5000/μl)

          -  renal insufficiency (creatinine&gt; 1.5 mg / dl)

          -  heart disease, condition after heart attack

          -  anemia (Hb &lt;12 g / l, controls at each examination), blood donation within 4 weeks
             before the examination

          -  participation in another study within 2 months before the examination

          -  wear a metal or magnetic objects on or in the body

          -  claustrophobia

          -  use of immunomodulatory drugs (cortisol, antihistamines, aspirin)

          -  thyroid disease

          -  taking glitazones and insulin therapy

          -  pregnancy, lactation, menstruation

          -  cigarette smoking, use of alcohol or drugs, psychiatric disorders

          -  risk for / or manifest AIDS (HIV) or hepatitis B or C

          -  liver disease is not attributed to the existence of a non-alcoholic steatosis

          -  night shift work or circumstances, which do not allow the normal day-night rhythm

          -  bleeding disorders or disorders in wound healing

          -  hypersensitivity to local anesthetics

          -  malignant cancer

          -  heart rhythm disorders

          -  polyneuropathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, MD, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Germyn Diabetic Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia Szendrödi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Diabetic Center</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein- Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Frangos E, Ellrich J, Komisaruk BR. Non-invasive Access to the Vagus Nerve Central Projections via Electrical Stimulation of the External Ear: fMRI Evidence in Humans. Brain Stimul. 2015 May-Jun;8(3):624-36. doi: 10.1016/j.brs.2014.11.018. Epub 2014 Dec 6.</citation>
    <PMID>25573069</PMID>
  </reference>
  <reference>
    <citation>Heni M, Wagner R, Kullmann S, Veit R, Mat Husin H, Linder K, Benkendorff C, Peter A, Stefan N, Häring HU, Preissl H, Fritsche A. Central insulin administration improves whole-body insulin sensitivity via hypothalamus and parasympathetic outputs in men. Diabetes. 2014 Dec;63(12):4083-8. doi: 10.2337/db14-0477. Epub 2014 Jul 15.</citation>
    <PMID>25028522</PMID>
  </reference>
  <results_reference>
    <citation>Gancheva S, Koliaki C, Bierwagen A, Nowotny P, Heni M, Fritsche A, Häring HU, Szendroedi J, Roden M. Effects of intranasal insulin on hepatic fat accumulation and energy metabolism in humans. Diabetes. 2015 Jun;64(6):1966-75. doi: 10.2337/db14-0892. Epub 2015 Jan 9.</citation>
    <PMID>25576060</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Diabetes Center</investigator_affiliation>
    <investigator_full_name>julia szendrödi</investigator_full_name>
    <investigator_title>Dr PhD</investigator_title>
  </responsible_party>
  <keyword>central insulin</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>energy metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

